

# Jack D Sobel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12057664/publications.pdf>

Version: 2024-02-01

276  
papers

33,734  
citations

9264

74  
h-index

3830

178  
g-index

288  
all docs

288  
docs citations

288  
times ranked

20957  
citing authors

#	ARTICLE	IF	CITATIONS
1	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 2008, 46, 1813-1821.	5.8	4,375
2	Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2009, 48, 503-535.	5.8	2,644
3	Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2016, 62, e1-e50.	5.8	2,489
4	Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2010, 50, 291-322.	5.8	2,195
5	Guidelines for Treatment of Candidiasis. Clinical Infectious Diseases, 2004, 38, 161-189.	5.8	1,371
6	Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2016, 62, 409-417.	5.8	1,258
7	Vulvovaginal candidosis. Lancet, The, 2007, 369, 1961-1971.	13.7	1,050
8	Urinary Tract Infection. Annals of Epidemiology, 2000, 10, 509-515.	1.9	828
9	<i>Candida glabrata</i> : Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison to <i>C. albicans</i> . Clinical Microbiology Reviews, 1999, 12, 80-96.	13.6	819
10	Treatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1997, 337, 15-21.	27.0	745
11	Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials. Clinical Infectious Diseases, 2012, 54, 1110-1122.	5.8	649
12	Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. American Journal of Obstetrics and Gynecology, 1998, 178, 203-211.	1.3	540
13	Vaginitis. New England Journal of Medicine, 1997, 337, 1896-1903.	27.0	450
14	Emerging Role of Lactobacilli in the Control and Maintenance of the Vaginal Bacterial Microflora. Clinical Infectious Diseases, 1990, 12, 856-872.	5.8	448
15	Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis. New England Journal of Medicine, 2004, 351, 876-883.	27.0	408
16	Recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology, 2016, 214, 15-21.	1.3	373
17	Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infectious Diseases, The, 2018, 18, e339-e347.	9.1	334
18	Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology, 1985, 152, 924-935.	1.3	300

#	ARTICLE	IF	CITATIONS
19	Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. <i>Clinical Infectious Diseases</i> , 2016, 63, 754-762.	5.8	281
20	Bacterial Vaginosis. <i>Annual Review of Medicine</i> , 2000, 51, 349-356.	12.2	251
21	Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 194, 1283-1289.	1.3	249
22	Prevalent mutator genotype identified in fungal pathogen <i>Candida glabrata</i> promotes multi-drug resistance. <i>Nature Communications</i> , 2016, 7, 11128.	12.8	227
23	Validity of the Vaginal Gram Stain for the Diagnosis of Bacterial Vaginosis. <i>Obstetrics and Gynecology</i> , 1996, 88, 573-576.	2.4	212
24	Recurrent Vulvovaginal Candidiasis. <i>New England Journal of Medicine</i> , 1986, 315, 1455-1458.	27.0	202
25	Prevalence of Recurrent Vulvovaginal Candidiasis in 5 European Countries and the United States. <i>Journal of Lower Genital Tract Disease</i> , 2013, 17, 340-345.	1.9	201
26	Empirical Fluconazole versus Placebo for Intensive Care Unit Patients. <i>Annals of Internal Medicine</i> , 2008, 149, 83.	3.9	191
27	Pathogenesis and Epidemiology of Vulvovaginal Candidiasis. <i>Annals of the New York Academy of Sciences</i> , 1988, 544, 547-557.	3.8	179
28	<i>Candida</i> Urinary Tract Infections—Epidemiology. <i>Clinical Infectious Diseases</i> , 2011, 52, S433-S436.	5.8	178
29	Reviews Of Antifungal Agents: Anidulafungin: A Novel Echinocandin. <i>Clinical Infectious Diseases</i> , 2006, 43, 215-222.	5.8	176
30	Prevalence and risk factors for vaginal <i>Candida</i> colonization in women with type 1 and type 2 diabetes. <i>BMC Infectious Diseases</i> , 2002, 2, 1.	2.9	174
31	Ocular Manifestations of Candidemia. <i>Clinical Infectious Diseases</i> , 2011, 53, 262-268.	5.8	171
32	Prophylactic Antifungal Therapy in the Intensive Care Unit. <i>Clinical Infectious Diseases</i> , 2001, 32, 1191-1200.	5.8	168
33	Nosocomial Acquisition of <i>Candida albicans</i> : An Epidemiologic Study. <i>Journal of Infectious Diseases</i> , 1993, 168, 195-201.	4.0	165
34	Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. <i>Obstetrics and Gynecology</i> , 2002, 99, 419-425.	2.4	160
35	Treatment of vaginitis caused by <i>Candida glabrata</i> : use of topical boric acid and flucytosine. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 189, 1297-1300.	1.3	160
36	<i>Candida</i> Urinary Tract Infections—Treatment. <i>Clinical Infectious Diseases</i> , 2011, 52, S457-S466.	5.8	157

#	ARTICLE	IF	CITATIONS
37	Current Treatment of Bacterial Vaginosis—Limitations and Need for Innovation. <i>Journal of Infectious Diseases</i> , 2016, 214, S14-S20.	4.0	156
38	Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 177-190.	1.3	152
39	Fluconazole-Resistant <i>Candida albicans</i> Vulvovaginitis. <i>Obstetrics and Gynecology</i> , 2012, 120, 1407-1414.	2.4	151
40	Comparison of 2 Doses of Liposomal Amphotericin B and Conventional Amphotericin B Deoxycholate for Treatment of AIDS-Associated Acute Cryptococcal Meningitis: A Randomized, Double-Blind Clinical Trial of Efficacy and Safety. <i>Clinical Infectious Diseases</i> , 2010, 51, 225-232.	5.8	150
41	Candidal Vulvovaginitis. <i>Clinical Obstetrics and Gynecology</i> , 1993, 36, 153-165.	1.1	143
42	MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting. <i>Clinical Infectious Diseases</i> , 2014, 58, 1219-1226.	5.8	142
43	A Phase II Randomized Trial of Amphotericin B Alone or Combined with Fluconazole in the Treatment of HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2009, 48, 1775-1783.	5.8	141
44	Single oral dose fluconazole compared with conventional clotrimazole topical therapy of <i>Candida</i> vaginitis. <i>American Journal of Obstetrics and Gynecology</i> , 1995, 172, 1263-1268.	1.3	135
45	A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis—A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2018, 66, 1928-1936.	5.8	134
46	<i>Candida</i> vaginitis. <i>Sexually Transmitted Diseases</i> , 2000, 27, 230-235.	1.7	133
47	Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. <i>BMC Women's Health</i> , 2019, 19, 48.	2.0	133
48	Desquamative inflammatory vaginitis: A new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy. <i>American Journal of Obstetrics and Gynecology</i> , 1994, 171, 1215-1220.	1.3	129
49	Nosocomial acquisition of <i>Candida parapsilosis</i> : An epidemiologic study. <i>American Journal of Medicine</i> , 1993, 94, 577-582.	1.5	124
50	Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. <i>Current Medical Research and Opinion</i> , 2014, 30, 1109-1119.	1.9	124
51	<i>Candida</i> Urinary Tract Infections—Diagnosis. <i>Clinical Infectious Diseases</i> , 2011, 52, S452-S456.	5.8	123
52	A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections. <i>Clinical Infectious Diseases</i> , 2015, 61, S837-S848.	5.8	121
53	Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive <i>Candida</i> Infections: The ACTIVE Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 1981-1989.	5.8	120
54	<i>Candida</i> Urinary Tract Infection: Pathogenesis. <i>Clinical Infectious Diseases</i> , 2011, 52, S437-S451.	5.8	113

#	ARTICLE	IF	CITATIONS
55	Nosocomial <i>Candida glabrata</i> Colonization: an Epidemiologic Study. Journal of Clinical Microbiology, 1998, 36, 421-426.	3.9	112
56	Cryptococcal Immune Reconstitution Inflammatory Syndrome after Antiretroviral Therapy in AIDS Patients with Cryptococcal Meningitis: A Prospective Multicenter Study. Clinical Infectious Diseases, 2009, 49, 931-934.	5.8	103
57	The role of cell-mediated immunity in candidiasis. Trends in Microbiology, 1994, 2, 202-206.	7.7	102
58	Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses, 2011, 54, 46-51.	4.0	98
59	Metronidazole-Resistant Vaginal Trichomoniasis – An Emerging Problem. New England Journal of Medicine, 1999, 341, 292-293.	27.0	97
60	Uropathogenic Escherichia coli Are More Likely than Commensal E. coli to Be Shared between Heterosexual Sex Partners. American Journal of Epidemiology, 2002, 156, 1133-1140.	3.4	96
61	Vulvovaginal Candidiasis Caused by Non-albicans Candida Species: New Insights. Current Infectious Disease Reports, 2010, 12, 465-470.	3.0	94
62	Mucosal candidiasis. Infectious Disease Clinics of North America, 2002, 16, 793-820.	5.1	93
63	What's New in Bacterial Vaginosis and Trichomoniasis?. Infectious Disease Clinics of North America, 2005, 19, 387-406.	5.1	93
64	Mucosal Candidal Colonization and Candidiasis in Women with or at Risk for Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 1998, 27, 1161-1167.	5.8	92
65	Vaginitis Due to <i>Candida krusei</i> : Epidemiology, Clinical Aspects, and Therapy. Clinical Infectious Diseases, 2002, 35, 1066-1070.	5.8	91
66	Effect of pH on <i>In Vitro</i> Susceptibility of <i>Candida glabrata</i> and <i>Candida albicans</i> to 11 Antifungal Agents and Implications for Clinical Use. Antimicrobial Agents and Chemotherapy, 2012, 56, 1403-1406.	3.2	91
67	Boric Acid Addition to Suppressive Antimicrobial Therapy for Recurrent Bacterial Vaginosis. Sexually Transmitted Diseases, 2009, 36, 732-734.	1.7	87
68	PATHOGENESIS OF URINARY TRACT INFECTION. Infectious Disease Clinics of North America, 1997, 11, 531-549.	5.1	85
69	Longitudinal Study of Mucosal <i>Candida</i> Species Colonization and Candidiasis among Human Immunodeficiency Virus (HIV) – Seropositive and At-Risk HIV – Seronegative Women. Journal of Infectious Diseases, 2003, 188, 118-127.	4.0	83
70	Caspofungin in the Treatment of Symptomatic Candiduria. Clinical Infectious Diseases, 2007, 44, e46-e49.	5.8	83
71	Is there a protective role for vaginal flora?. Current Infectious Disease Reports, 1999, 1, 379-383.	3.0	82
72	High-Frequency, <i>In Vitro</i> Reversible Switching of <i>Candida lusitanae</i> Clinical Isolates from Amphotericin B Susceptibility to Resistance. Antimicrobial Agents and Chemotherapy, 1999, 43, 836-845.	3.2	81

#	ARTICLE	IF	CITATIONS
73	Antifungal drugs in pregnancy: a review. Expert Opinion on Drug Safety, 2003, 2, 475-483.	2.4	80
74	The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia. Current Infectious Disease Reports, 2006, 8, 427-433.	3.0	78
75	Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: Results of a prospective cohort study. American Journal of Obstetrics and Gynecology, 2004, 190, 644-653.	1.3	77
76	Mixed Vaginitis—More Than Coinfection and With Therapeutic Implications. Current Infectious Disease Reports, 2013, 15, 104-108.	3.0	77
77	Effect of Antibiotics on Vulvovaginal Candidiasis: A MetroNet Study. Journal of the American Board of Family Medicine, 2008, 21, 261-268.	1.5	76
78	Frequency and Response to Vaginal Symptoms among White and African American Women: Results of a Random Digit Dialing Survey. Journal of Women's Health, 1998, 7, 1167-1174.	0.9	75
79	The Evolution of Candida Species and Fluconazole Susceptibility among Oral and Vaginal Isolates Recovered from Human Immunodeficiency Virus (HIV)—Seropositive and At-Risk HIV—Seronegative Women. Journal of Infectious Diseases, 2001, 183, 286-293.	4.0	75
80	Urinary tract infection among women aged 40 to 65. Journal of Clinical Epidemiology, 2001, 54, 710-718.	5.0	74
81	Development and Validation of a Highly Accurate Quantitative Real-Time PCR Assay for Diagnosis of Bacterial Vaginosis. Journal of Clinical Microbiology, 2016, 54, 1017-1024.	3.9	74
82	A Randomized Study of the Use of Fluconazole in Continuous versus Episodic Therapy in Patients with Advanced HIV Infection and a History of Oropharyngeal Candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clinical Infectious Diseases, 2005, 41, 1473-1480.	5.8	72
83	Fluconazole for the treatment of candidiasis: 15 years experience. Expert Review of Anti-Infective Therapy, 2004, 2, 357-366.	4.4	71
84	Development and verification of fingerprinting probes for Candida glabrata. Microbiology (United Kingdom), 2004, 148, 1017-1024.	1.8	70
85	Practice Guidelines for the Treatment of Fungal Infections. Clinical Infectious Diseases, 2000, 30, 652-652.	5.8	70
86	Genital Mycotic Infections in Patients With Diabetes. Postgraduate Medicine, 2013, 125, 33-46.	2.0	70
87	Difficult to Treat Trichomoniasis: Results with Paromomycin Cream. Clinical Infectious Diseases, 1998, 26, 986-988.	5.8	69
88	A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered AVT-1161 in the treatment of recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology, 2018, 218, 624.e1-624.e9.	1.3	68
89	Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. American Journal of Obstetrics and Gynecology, 2019, 220, 91.e1-91.e8.	1.3	67
90	Gene polymorphisms in pattern recognition receptors and susceptibility to idiopathic recurrent vulvovaginal candidiasis. Frontiers in Microbiology, 2014, 5, 483.	3.5	66

#	ARTICLE	IF	CITATIONS
91	Experimental chronic vaginal candidosis in rats. <i>Medical Mycology</i> , 1985, 23, 199-206.	0.7	65
92	A Combination Fluorescence Assay Demonstrates Increased Efflux Pump Activity as a Resistance Mechanism in Azole-Resistant Vaginal <i>Candida albicans</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5858-5866.	3.2	64
93	Gynecologic Infections in Human Immunodeficiency Virus-Infected Women. <i>Clinical Infectious Diseases</i> , 2000, 31, 1225-1233.	5.8	61
94	Management of Patients with Recurrent Vulvovaginal Candidiasis. <i>Drugs</i> , 2003, 63, 1059-1066.	10.9	60
95	Prognosis and Treatment of Desquamative Inflammatory Vaginitis. <i>Obstetrics and Gynecology</i> , 2011, 117, 850-855.	2.4	60
96	FUNGAL INFECTIONS IN DIABETES. <i>Infectious Disease Clinics of North America</i> , 1995, 9, 97-116.	5.1	58
97	Fungicidal Activity of Fluconazole against <i>Candida albicans</i> in a Synthetic Vagina-Simulative Medium. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 161-167.	3.2	57
98	Identification of intrinsically metronidazole-resistant clades of <i>Gardnerella vaginalis</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 84, 1-3.	1.8	57
99	Treatment Options for Vulvovaginal Candidiasis, 1993. <i>Clinical Infectious Diseases</i> , 1995, 20, S80-S90.	5.8	55
100	Evolution of Antifungal Susceptibility among <i>Candida</i> Species Isolates Recovered from Human Immunodeficiency Virus-Infected Women Receiving Fluconazole Prophylaxis. <i>Clinical Infectious Diseases</i> , 2001, 33, 1069-1075.	5.8	54
101	Longitudinal Analysis of Vaginal Microbiome Dynamics in Women with Recurrent Bacterial Vaginosis: Recognition of the Conversion Process. <i>PLoS ONE</i> , 2013, 8, e82599.	2.5	53
102	Metronidazole for the treatment of vaginal infections. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1109-1115.	1.8	52
103	Emerging azole antifungals. <i>Expert Opinion on Emerging Drugs</i> , 2005, 10, 21-33.	2.4	50
104	Pathogenesis of recurrent vulvovaginal candidiasis. <i>Current Infectious Disease Reports</i> , 2002, 4, 514-519.	3.0	49
105	Use of Antifungal Drugs in Pregnancy. <i>Drug Safety</i> , 2000, 23, 77-85.	3.2	48
106	Reduced fluconazole susceptibility of <i>Candida albicans</i> isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 64, 354-356.	1.8	48
107	Vulvovaginal Candidiasis—What We Do and Do Not Know. <i>Annals of Internal Medicine</i> , 1984, 101, 390.	3.9	46
108	Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: Risk factors and severity. <i>Obstetrics and Gynecology</i> , 2003, 101, 548-556.	2.4	46

#	ARTICLE	IF	CITATIONS
109	Treatment of vaginal Candida infections. Expert Opinion on Pharmacotherapy, 2002, 3, 1059-1065.	1.8	43
110	Experimental Models of Vaginal Candidiasis and Their Relevance to Human Candidiasis. Infection and Immunity, 2016, 84, 1255-1261.	2.2	42
111	Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis. Future Microbiology, 2021, 16, 1453-1461.	2.0	42
112	Echinocandins â€” First-Choice or First-Line Therapy for Invasive Candidiasis?. New England Journal of Medicine, 2007, 356, 2525-2526.	27.0	41
113	Bacterial Vaginosis-An Ecologic Mystery. Annals of Internal Medicine, 1989, 111, 551.	3.9	40
114	Vulvovaginal candidiasis. Obstetrics and Gynecology Clinics of North America, 2003, 30, 671-684.	1.9	39
115	A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis. Clinical Infectious Diseases, 2021, 73, e1518-e1524.	5.8	39
116	Stable Phenotypic Resistance of <i>Candida</i> Species to Amphotericin B Conferred by Preexposure to Subinhibitory Levels of Azoles. Journal of Clinical Microbiology, 1998, 36, 2690-2695.	3.9	39
117	Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis. Expert Opinion on Investigational Drugs, 2020, 29, 893-900.	4.1	38
118	Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303). Clinical Infectious Diseases, 2022, 74, 1979-1985.	5.8	38
119	Bacterial vaginosis: drivers of recurrence and challenges and opportunities in partner treatment. BMC Medicine, 2021, 19, 194.	5.5	38
120	vaginitis: Transmission from yeast used in baking. Obstetrics and Gynecology, 1995, 86, 326-329.	2.4	37
121	Dynamics of the Vaginal Ecosystemâ€™Hormonal Influences. Infectious Diseases: Research and Treatment, 2010, 3, IDRT.S3903.	1.7	37
122	Bacterial vaginosis: Culture- and PCR-based characterizations of a complex polymicrobial diseaseâ€™s pathobiology. Current Infectious Disease Reports, 2007, 9, 485-500.	3.0	34
123	Pathogenesis of Candida Vulvovaginitis. Current Topics in Medical Mycology, 1989, 3, 86-108.	0.8	34
124	Pathogenesis of Urinary Tract Infections Host Defenses. Infectious Disease Clinics of North America, 1987, 1, 751-772.	5.1	32
125	Septic Shock Due to Candidemia: Outcomes and Predictors of Shock Development. Journal of Clinical Medicine Research, 2011, 3, 65-71.	1.2	32
126	Incident and Persistent Vulvovaginal Candidiasis Among Human Immunodeficiency Virusâ€™Infected Women. Obstetrics and Gynecology, 2003, 101, 548-556.	2.4	31



#	ARTICLE	IF	CITATIONS
127	Miconazole Mucoadhesive Tablets: A Novel Delivery System. <i>Clinical Infectious Diseases</i> , 2012, 54, 1480-1484.	5.8	31
128	Diagnosing vaginal infections through measurement of biogenic amines by ion mobility spectrometry. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2012, 163, 81-84.	1.1	31
129	Factors involved in patient choice of oral or vaginal treatment for vulvovaginal candidiasis. <i>Patient Preference and Adherence</i> , 2013, 8, 31.	1.8	31
130	CX <sub>3</sub> CR1 Is Dispensable for Control of Mucosal <i>Candida albicans</i> Infections in Mice and Humans. <i>Infection and Immunity</i> , 2015, 83, 958-965.	2.2	31
131	Vulvovaginal Candidiasis Complicating Recurrent Bacterial Vaginosis. <i>Sexually Transmitted Diseases</i> , 1990, 17, 51-53.	1.7	29
132	Multiplex quantitative polymerase chain reaction assay for the identification and quantitation of major vaginal lactobacilli. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 78, 321-327.	1.8	29
133	Prognostic Indicators of Recurrence of Bacterial Vaginosis. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	29
134	Vulvovaginal candidiasis: a comparison of HIV-positive and -negative women. <i>International Journal of STD and AIDS</i> , 2002, 13, 358-362.	1.1	28
135	Association between Semen Exposure and Incident Bacterial Vaginosis. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2011, 2011, 1-10.	1.5	28
136	In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against <i>Candida</i> spp. isolates from patients with vulvovaginal candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1355-1358.	3.0	28
137	Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by <i>Candida albicans</i> . <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 48-52.	1.9	28
138	Vulvovaginitis. <i>Dermatologic Clinics</i> , 1992, 10, 339-359.	1.7	27
139	Desquamative Inflammatory Vaginitis An Exploratory Case-Control Study. <i>Annals of Epidemiology</i> , 2002, 12, 346-352.	1.9	27
140	Management of recurrent vulvovaginal candidiasis: Unresolved issues. <i>Current Infectious Disease Reports</i> , 2006, 8, 481-486.	3.0	27
141	Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306). <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 412-420.	2.3	27
142	Recurrent Group A Streptococcal Vulvovaginitis in Adult Women: Family Epidemiology. <i>Clinical Infectious Diseases</i> , 2007, 44, e43-e45.	5.8	25
143	Editorial Commentary: Vaginal Biofilm: Much Ado About Nothing, or a New Therapeutic Challenge?. <i>Clinical Infectious Diseases</i> , 2015, 61, 607-608.	5.8	25
144	Utilization of molecular methods to identify prognostic markers for recurrent bacterial vaginosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 86, 231-242.	1.8	25

#	ARTICLE	IF	CITATIONS
145	Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines. <i>Clinical Infectious Diseases</i> , 2022, 74, S162-S168.	5.8	25
146	Zinc status in women with recurrent vulvovaginal candidiasis. <i>American Journal of Obstetrics and Gynecology</i> , 1986, 155, 1082-1085.	1.3	23
147	Recurrent Vulvovaginal Candidiasis. <i>Obstetrics and Gynecology</i> , 1986, 67, 810-812.	2.4	23
148	Controversial aspects in the management of vulvovaginal candidiasis. <i>Journal of the American Academy of Dermatology</i> , 1994, 31, S10-S13.	1.2	23
149	Shuttle vectors for <i>Candida albicans</i> : control of plasmid copy number and elevated expression of cloned genes. <i>Current Genetics</i> , 2004, 45, 390-398.	1.7	23
150	<i>Candida</i> vulvovaginitis: A store with a butterfly and a show window. <i>Mycoses</i> , 2017, 60, 70-72.	4.0	23
151	VULVOVAGINITIS. <i>Dermatologic Clinics</i> , 1998, 16, 763-768.	1.7	22
152	A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis. <i>Sexually Transmitted Diseases</i> , 2015, 42, 376-381.	1.7	22
153	Urinary Excretion of Tamm-Horsfall Protein in Elderly Women. <i>Journal of Urology</i> , 1991, 146, 806-808.	0.4	21
154	Guidelines for the treatment of bacterial vaginosis: focus on tinidazole. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 485.	2.0	21
155	Pathogenesis of Bacteriuria in Elderly Women: The Role of <i>Escherichia Coli</i> Adherence to Vaginal Epithelial Cells. <i>Journal of Gerontology</i> , 1984, 39, 682-685.	1.9	20
156	Recurrent vulvovaginal candidiasis associated with long-term tamoxifen treatment in postmenopausal women. <i>Obstetrics and Gynecology</i> , 1996, 88, 704-706.	2.4	20
157	The Association Between <i>Trichomonas</i> Infection and Incarceration in HIV-Seropositive and At-Risk HIV-Seronegative Women. <i>Sexually Transmitted Diseases</i> , 2011, 38, 1094-1100.	1.7	20
158	Novel PCR-Based Methods Enhance Characterization of Vaginal Microbiota in a Bacterial Vaginosis Patient before and after Treatment. <i>Applied and Environmental Microbiology</i> , 2013, 79, 4181-4185.	3.1	20
159	High-Dose Vaginal Maintenance Metronidazole for Recurrent Bacterial Vaginosis. <i>Sexually Transmitted Diseases</i> , 2014, 41, 290-291.	1.7	20
160	Failure of Nitazoxanide to Cure <i>Trichomoniasis</i> in Three Women. <i>Sexually Transmitted Diseases</i> , 2007, 34, 813-814.	1.7	20
161	Combination Therapy for Invasive Mycoses: Evaluation of Past Clinical Trial Designs. <i>Clinical Infectious Diseases</i> , 2004, 39, S224-S227.	5.8	19
162	Comparative in Vitro Activity of Antiseptics and Disinfectants Versus Clinical Isolates of <i>Candida</i> Species. <i>Infection Control and Hospital Epidemiology</i> , 1999, 20, 676-684.	1.8	18

#	ARTICLE	IF	CITATIONS
163	Antibiotic-associated vulvovaginal candidiasis. Current Infectious Disease Reports, 2003, 5, 481-487.	3.0	18
164	advances in diagnosing vaginitis: Development of a new algorithm. Current Infectious Disease Reports, 2005, 7, 458-462.	3.0	18
165	The VI-SENSE™ vaginal discharge self-test to facilitate management of vaginal symptoms. American Journal of Obstetrics and Gynecology, 2006, 195, 1351-1356.	1.3	18
166	Candida glabrata complicating in vitro pregnancy: successful management of subsequent pregnancy. Fertility and Sterility, 2011, 95, 803.e1-803.e2.	1.0	18
167	Treatment of Male Sexual Partners of Women With Bacterial Vaginosis: A Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases, 2021, 73, e672-e679.	5.8	18

168

#	ARTICLE	IF	CITATIONS
181	Apthous vaginal ulceration in two women with acquired immunodeficiency syndrome. American Journal of Obstetrics and Gynecology, 1996, 174, 1660-1663.	1.3	14
182	Vaginal Mucormycosis: A Case Report. Infectious Diseases in Obstetrics and Gynecology, 2001, 9, 117-118.	1.5	14
183	Tinidazole for the treatment of vaginal infections. Expert Opinion on Investigational Drugs, 2007, 16, 743-751.	4.1	14
184	Dense Genotyping of Immune-Related Loci Identifies Variants Associated with Clearance of HPV among HIV-Positive Women in the HIV Epidemiology Research Study (HERS). PLoS ONE, 2014, 9, e99109.	2.5	14
185	A Role for Yeast/Pseudohyphal Cells of Candida albicans in the Correlated Expression of NLRP3 Inflammasome Inducers in Women With Acute Vulvovaginal Candidiasis. Frontiers in Microbiology, 2019, 10, 2669.	3.5	14
186	Recurrent Bacterial Vaginosis: An Unmet Therapeutic Challenge. Experience With a Combination Pharmacotherapy Long-Term Suppressive Regimen. Sexually Transmitted Diseases, 2021, 48, 761-765.	1.7	14
187	The Role of Antimicrobial Resistance in Refractory and Recurrent Bacterial Vaginosis and Current Recommendations for Treatment. Antibiotics, 2022, 11, 500.	3.7	14
188	Limitations of antifungal agents in the treatment of Candida vaginitis: future challenges. Drug Resistance Updates, 1999, 2, 148-152.	14.4	13
189	Genital candidiasis. Medicine, 2005, 33, 62-65.	0.4	13
190	Antibiotic consideration in bacterial vaginosis. Current Infectious Disease Reports, 2009, 11, 471-475.	3.0	13
191	Candida kefyr Endocarditis in a Patient With Hypertrophic Obstructive Cardiomyopathy. American Journal of the Medical Sciences, 2010, 339, 188-189.	1.1	13
192	Vulvovaginal candidiasis: An overview of mycological, clinical, and immunological aspects. Journal of Obstetrics and Gynaecology Research, 2022, 48, 1546-1560.	1.3	13
193	Individualizing treatment of vaginal candidiasis. Journal of the American Academy of Dermatology, 1990, 23, 572-576.	1.2	12
194	Management of infections caused by Candida glabrata. Current Infectious Disease Reports, 2000, 2, 424-428.	3.0	12
195	Cytokine/chemokine expression associated with Human Pegivirus (HPgV) infection in women with HIV. Journal of Medical Virology, 2017, 89, 1904-1911.	5.0	12
196	Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis. Clinical Infectious Diseases, 2022, 74, 2129-2135.	5.8	12
197	Accuracy of Clinical Diagnosis of Bacterial Vaginosis by Human Immunodeficiency Virus Infection Status. Sexually Transmitted Diseases, 2011, 38, 270-274.	1.7	12
198	Nontrichomonal purulent vaginitis: Clinical approach. Current Infectious Disease Reports, 2000, 2, 501-505.	3.0	11

#	ARTICLE	IF	CITATIONS
199	High-Dose Vaginal Metronidazole for Recurrent Bacterial Vaginosis—A Pilot Study. <i>Journal of Lower Genital Tract Disease</i> , 2014, 18, 156-161.	1.9	11
200	Current and emerging pharmacotherapy for recurrent bacterial vaginosis. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1593-1600.	1.8	11
201	<i>In Vitro</i> pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant <i>Candida</i> Isolates from Women with Vulvovaginal Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0056221.	3.2	11
202	A New Slide Latex Agglutination Test for the Diagnosis of Acute Candida Vaginitis. <i>American Journal of Clinical Pathology</i> , 1990, 94, 323-325.	0.7	10
203	Protozoan-Viral-Bacterial Co-Infections Alter Galectin Levels and Associated Immunity Mediators in the Female Genital Tract. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 649940.	3.9	10
204	Vulvovaginal Trichosporonosis. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2003, 11, 131-133.	1.5	9
205	Elevated COVID19 mortality risk in Detroit area hospitals among patients from census tracts with extreme socioeconomic vulnerability. <i>EClinicalMedicine</i> , 2021, 34, 100814.	7.1	9
206	Mixed Vaginitis Due to Bacterial Vaginosis and Candidiasis. <i>Journal of Lower Genital Tract Disease</i> , 2022, 26, 68-70.	1.9	9
207	Women and AIDS. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1993, 33, 341-350.	1.0	8
208	Diagnostic techniques for bacterial vaginosis and vulvovaginal candidiasis — requirement for a simple differential test. <i>Expert Opinion on Medical Diagnostics</i> , 2010, 4, 333-341.	1.6	8
209	GB Virus C (GBV-C) Infection in Hepatitis C Virus (HCV) Seropositive Women with or at Risk for HIV Infection. <i>PLoS ONE</i> , 2014, 9, e114467.	2.5	8
210	In Vitro Antifungal Activity of CAN-296: A Naturally Occurring Complex Carbohydrate.. <i>Journal of Antibiotics</i> , 1997, 50, 937-943.	2.0	7
211	Involvement of calcium inhibitable binding to the cell wall in the fungicidal activity of CAN-296. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 217-222.	3.0	7
212	Over-the-Counter Antifungal Drug Misuse Associated With Patient-Diagnosed Vulvovaginal Candidiasis. <i>Obstetrics and Gynecology</i> , 2002, 99, 419-425.	2.4	7
213	Design of Clinical Trials of Empiric Antifungal Therapy in Patients with Persistent Febrile Neutropenia: Considerations and Critiques. <i>Pharmacotherapy</i> , 2006, 26, 47S-54S.	2.6	7
214	Genital candidiasis. <i>Medicine</i> , 2010, 38, 286-290.	0.4	7
215	A case of <i>Conidiobolus coronatus</i> in the vagina. <i>Medical Mycology</i> , 2011, 49, 427-429.	0.7	7
216	Syndromic Treatment of Women With Vulvovaginal Symptoms in the United States: A Call to Action!. <i>Clinical Infectious Diseases</i> , 2021, 72, 1544-1545.	5.8	7

#	ARTICLE	IF	CITATIONS
217	Steroid therapy of vulvovaginal lichen planus. <i>Current Infectious Disease Reports</i> , 2002, 4, 507-508.	3.0	6
218	CAN-296-P is effective against cutaneous candidiasis in guinea pigs. <i>International Journal of Antimicrobial Agents</i> , 2003, 22, 168-171.	2.5	6
219	The emergence of non-albicans <i>Candida</i> species as causes of invasive candidiasis and candidemia. <i>Current Fungal Infection Reports</i> , 2007, 1, 42-48.	2.6	6
220	Use of the VS-Sense Swab in Diagnosing Vulvovaginitis. <i>Journal of Women's Health</i> , 2009, 18, 1467-1470.	3.3	6
221	Genital Malodor in Women. <i>Journal of Lower Genital Tract Disease</i> , 2012, 16, 49-55.	1.9	6
222	Vaginitis, Vulvitis, Cervicitis and Cutaneous Vulval Lesions. , 2017, , 483-491.e1.		6
223	<i>Candida</i> Vaginitis. <i>Infectious Diseases in Clinical Practice</i> , 1994, 3, 334-339.	0.3	5
224	Antimicrobial resistance in vulvovaginitis. <i>Current Infectious Disease Reports</i> , 2001, 3, 546-549.	3.0	5
225	Tinidazole for bacterial vaginosis. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 343-348.	4.4	5
226	Antifungal Targets, Mechanisms of Action, and Resistance in <i>Candida albicans</i> . , 2009, , 347-407.		5
227	Douching for Perceived Vaginal Odor With No Infectious Cause of Vaginitis. <i>Journal of Lower Genital Tract Disease</i> , 2011, 15, 128-133.	1.9	5
228	Algorithms for Managing Vulvovaginal Symptoms—a Practical Primer. <i>Current Infectious Disease Reports</i> , 2019, 21, 40.	3.0	5
229	Diversity of the hepatitis C virus NS5B gene during HIV co-infection. <i>PLoS ONE</i> , 2020, 15, e0237162.	2.5	5
230	Data on Safety of Intravaginal Boric Acid Use in Pregnant and Nonpregnant Women: A Narrative Review. <i>Sexually Transmitted Diseases</i> , 2021, 48, e241-e247.	1.7	5
231	Antifungal Bladder Irrigation. <i>Infectious Diseases in Clinical Practice</i> , 2006, 14, 125-126.	0.3	4
232	A Case of High-Level Metronidazole-Resistant Trichomoniasis in Pregnancy Successfully Treated. <i>Journal of Lower Genital Tract Disease</i> , 2011, 15, 248-249.	1.9	4
233	The Role of Resistance in <i>Candida</i> Infections: Epidemiology and Treatment. , 2017, , 1075-1097.		4
234	Vaginal Isolates of <i>Candida glabrata</i> Are Uniquely Susceptible to Ionophoric Killer Toxins Produced by <i>Saccharomyces cerevisiae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0245020.	3.2	4

#	ARTICLE	IF	CITATIONS
235	Comparative study of intravaginal metronidazole and triple-sulfa therapy for bacterial vaginosis. Infectious Diseases in Obstetrics and Gynecology, 1996, 4, 66-70.	1.5	4
236	Trichomoniasis as seen in a chronic vaginitis clinic. Infectious Diseases in Obstetrics and Gynecology, 1996, 4, 77-84.	1.5	4
237	Use of a Novel Couples' Verification Tool in a Male Partner Treatment Study of Women With Recurrent Bacterial Vaginosis. Sexually Transmitted Diseases, 2020, 47, e58-e61.	1.7	4
238	Mucosal Candidiasis. , 0, , 417-427.		4
239	Determining Susceptibility in <i>Candida</i> Vaginal Isolates. Antimicrobial Agents and Chemotherapy, 0, , .	3.2	4
240	Candida glabrata: an important fungal pathogen for the 21st century. Clinical Microbiology Newsletter, 2001, 23, 171-176.	0.7	3
241	Yeast Infections of the Lower Urinary Tract: Recommendations for Diagnosis and Treatment. Current Fungal Infection Reports, 2010, 4, 175-178.	2.6	3
242	Fungal Infections. Infectious Disease Clinics of North America, 2016, 30, xiii-xiv.	5.1	3
243	Antifungal Targets, Mechanisms of Action, and Resistance in Candida albicans. , 2017, , 429-475.		3
244	Therapeutic Considerations in Fungal Vaginitis. Handbook of Experimental Pharmacology, 1990, , 365-383.	1.8	3
245	Antimicrobial Susceptibility of Microbiota in Bacterial Vaginosis Using Fluorescence In Situ Hybridization. Pathogens, 2022, 11, 456.	2.8	3
246	Management of Vaginosis. Drug Investigation, 1994, 8, 26-34.	0.6	2
247	Estrogen replacement therapy to prevent recurrent urinary tract infection in postmenopausal women. Current Infectious Disease Reports, 2003, 5, 479-480.	3.0	2
248	Erosive vulvovaginitis. Current Infectious Disease Reports, 2003, 5, 494-498.	3.0	2
249	Chronic Pain of the Vulva without Dermatologic Manifestations: Distinguishing among a Spectrum of clinical Disorders. Clinical Medicine Insights Women's Health, 2010, 3, CMWH.S3950.	0.6	2
250	Are Echinocandins Better Than Azoles for Invasive Candidiasis?. Current Fungal Infection Reports, 2013, 7, 79-82.	2.6	2
251	Bacterial Vaginosis. , 2017, , 165-174.		2
252	The Vaginal Microbiota in Menopause. , 2010, , 883-893.		2

#	ARTICLE	IF	CITATIONS
253	Progress in antifungal therapy: Echinocandins versus azoles. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 221-226.	0.5	1
254	Fungal infections of the genitourinary tract. , 2009, , 547-559.		1
255	Re: A systematic review of drug treatment of vulvodynia: evidence of a strong placebo effect. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 945-946.	2.3	1
256	Comparative Study of Intravaginal Metronidazole and Triple-Sulfa Therapy for Bacterial Vaginosis. Infectious Diseases in Obstetrics and Gynecology, 1996, 4, 66-70.	1.5	1
257	Vaginitis, vulvitis, cervicitis and cutaneous vulval lesions. , 2010, , 542-550.		1
258	Genital Candidiasis. , 2011, , 613-624.		1
259	Current trends and challenges in candidiasis. Oncology, 2004, 18, 7-8.	0.5	1
260	Ibrexafungerp for the treatment of vulvovaginal candidiasis. Drugs of Today, 2022, 58, 149-158.	1.1	1
261	Mass or syndromic treatment of sexually transmitted infections. Current Infectious Disease Reports, 1999, 1, 365-366.	3.0	0
262	Alternative treatment modalities for prevention of urinary tract infection in women: Lactobacilli or cranberry juice?. Current Infectious Disease Reports, 2001, 3, 527-528.	3.0	0
263	Oral and vaginal antifungal treatments are similarly effective for vulvovaginal candidiasis â€“ meta-analysis. Evidence-Based Obstetrics and Gynecology, 2002, 4, 158-159.	0.0	0
264	Candiduria. , 0, , 457-460.		0
265	1411Utilization of PCR to Characterize Vaginal Flora in a Longitudinal Study of Recurrent Bacterial Vaginosis. Open Forum Infectious Diseases, 2014, 1, S371-S372.	0.9	0
266	Non-<i>albicans Candida</i> Infections. , 0, , 393-411.		0
267	Candiduria. , 0, , 430-433.		0
268	Reply. American Journal of Obstetrics and Gynecology, 2017, 216, 427.	1.3	0
269	Good Clinical Practice in Diagnosis of Vulvovaginal Symptoms. JAMA Internal Medicine, 2018, 178, 1135.	5.1	0
270	Desquamative Inflammatory Vaginitis as an Extraintestinal Manifestation of Crohnâ€™s Disease. Current Infectious Disease Reports, 2020, 22, 1.	3.0	0



#	ARTICLE	IF	CITATIONS
271	Donald Kaye: 1931–2020, in Memoriam. Clinical Infectious Diseases, 2021, 72, 2244-2245.	5.8	0
272	Genital Candidosis. Medicine, 2001, 29, 67-73.	0.4	0
273	Algorithm for Managing Vulvovaginal Symptoms. , 2021, , 544-551.		0
274	Non-infectious Benign Vaginal Conditions. , 2021, , 257-265.		0
275	Lower Genital Tract Microbiome—A Work in Progress. Journal of Lower Genital Tract Disease, 2022, 26, 71-72.	1.9	0
276	Desquamative Inflammatory Vaginitis as an Expression of Systemic Lupus Erythematosus. Journal of Lower Genital Tract Disease, 0, Publish Ahead of Print, .	1.9	0